Engineered immune cells take on lupus and scleroderma in early trial
NCT ID NCT07038447
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. KITE-363 is a type of cell therapy where a patient's own immune cells are modified in a lab to target and attack faulty immune cells. The study will enroll 52 participants and aims to find a safe dose and see if the therapy can reduce disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KITE-363 (a CAR T-cell therapy targeting CD19 and CD20)
- What this could lead to
- If successful, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to standard therapies.
- What could go wrong
- This is an early phase 1 trial with only 52 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects from the chemotherapy and the cell therapy itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Concord Repatriation General Hospital
Syndey, New South Wales, 2139, Australia
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Jewish General Hospital
Montreal, H3T1E2, Canada
-
St Vincent's Hospital
Fitzroy, Victoria, 3065, Australia
-
Stanford University
Stanford, California, 94305, United States
-
Tampa General Hospital Cancer Institute
Tampa, Florida, 33606, United States
-
The Ottawa Hospital, General Campus
Ottawa, K1H 8L6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Immune clues in the blood may foretell heart trouble